BFRI

Biofrontera is a $12M micro-cap dermatology pharma (Ameluz PDT for actinic keratosis) with a genuinely improving operating story wrapped in a dangerous balance sheet. The top line is durable and growing — revenue has climbed every year from $24.1M (FY2021) to $41.7M (FY2025, +11.7% YoY) — and losses are narrowing fast: net loss shrank to -$10.5M (+40.7% YoY) and operating loss to -$11.3M. Management's October 2025 Strategic Transaction, which bought the U.S. rights to Ameluz/RhodoLED and swapped a transfer-pricing model for a 12%/15%-of-revenue earnout, is explicitly framed as reducing cost and accelerating the path to break-even, and the November Xepi divestiture adds $3M (plus up to $7M milestones) of non-dilutive cash. At 0.3x sales, the equity is optically cheap.

The problem is solvency and survival, not the product. Operating cash flow was -$13.4M in FY2025 and getting worse (-30.1% YoY) against just $6.39M of cash — under a year of runway even with the Xepi proceeds. Stockholders' equity is a thin $10.5M sitting on a -$128M accumulated deficit, liabilities are 1.73x equity, and shares outstanding jumped 31.3% in a year, so the recent equity 'improvement' was bought with dilution that also depresses EPS. ROE of -100.5% reflects a company consuming its capital base.